# Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg

> **NCT00648024** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 47 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Anagrelide Hydrochloride Capsules 1 mg
- **DRUG:** Agrylin® Capsules 1 mg

## Key facts

- **NCT ID:** NCT00648024
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2003-01
- **Final completion:** 2003-01
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00648024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00648024, "Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00648024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*